> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Montana’s First Experimental Treatment Awaits Clinic License
- URL: https://www.theamericanquorum.com/state-news-montana-2026-09-22-b/
- Published: 2026-09-23T03:46:28.000Z
- Updated: 2026-09-23T03:46:28.000Z
- Description: Montana’s private review board has cleared its first experimental therapy, but no patient can receive it until the state licenses a treatment center—testing the safeguards in a new and unusually broad access system.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, Montana

Montana’s new experimental-treatment system has cleared its first therapy for review-board use, but patients still cannot receive it because the state has not licensed a treatment center.

The privately operated Montana Experimental Treatment Review Board announced its [first decision on Aug. 31](https://www.montanaetrb.org/?ref=theamericanquorum.com). Business Insider identified the treatment as a 30-day program from Parley Neurotech that combines targeted sound sessions with an antihistamine prescribed off label for people with central hearing loss. The company says its combination has [not been reviewed by the Food and Drug Administration](https://parleyneuro.com/montana?ref=theamericanquorum.com) for efficacy.

According to [Business Insider’s Sept. 15 investigation](https://www.businessinsider.com/montana-right-to-try-prospera-biotech-experimental-treatment-anzinger-2026-9?ref=theamericanquorum.com), Montana had not issued a license to any experimental-treatment center and two applications remained incomplete. That means the board’s approval does not by itself permit a clinic to begin treating patients.

The program is governed by rules the Montana Department of Public Health and Human Services adopted effective July 25\. The [46-page rulemaking order](https://dphhs.mt.gov/assets/rules/2026-427-Adp-Arm.pdf?ref=theamericanquorum.com) requires a center to establish or contract with a review board of at least five members, including a Montana-licensed physician, a clinical-outcomes researcher and an ethicist. Board members may not hold a personal, financial, employment or ownership interest in the treatment center they oversee.

Those rules also require each board to assess safety standards, informed consent, risk and alternatives before approving a protocol. Centers must report serious adverse events to the state within five days, maintain treatment and outcome records, and document that a patient evaluated and attempted FDA-approved options. Review boards must publish an annual summary of approvals and aggregate safety outcomes.

Montana’s pathway is broader than the federal Right to Try framework. The [FDA says federal eligibility](https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/right-try?ref=theamericanquorum.com) is limited to patients with life-threatening conditions who have exhausted approved options and cannot join a relevant clinical trial. Montana’s law can cover people without a terminal or life-threatening diagnosis, provided its state requirements are met.

The first board is not a state agency. It is operated by a private company affiliated with biotech investor Niklas Anzinger, and Business Insider reported that it charges companies $12,500 per application. The board says its role is a process-level safety review, not a guarantee that a treatment is safe or effective, and that its decisions create no federal legal status.

Supporters argue the model can give small biotechnology companies and willing patients a faster route to investigational therapies after early safety testing. Critics cited by Business Insider question whether private review, application fees and industry ties create conflicts or expose patients to treatments without adequate evidence of benefit. The state’s conflict rules address board members’ ties to treatment centers, while the department retains licensing and inspection authority over the centers themselves.

The next operational milestone is therefore not another board vote but a license from DPHHS. Until a compliant center opens, Parley’s approval remains a test of Montana’s oversight structure rather than an available treatment. Patients considering any investigational therapy should understand that board approval is not FDA approval and should discuss risks, alternatives and evidence with a licensed clinician.